# OnCo record da-semaglutide-evoke (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/da-semaglutide-evoke/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "da-semaglutide-evoke" ;
  schema:name "Semaglutide (EVOKE programme)"@en ;
  schema:description "Semaglutide is FDA-approved for other indications. Alzheimer’s disease use remains investigational in Phase 3 EVOKE studies, not a dementia label."@en ;
  schema:url <https://onco.cc/drugs/da-semaglutide-evoke/> ;
  schema:dateModified "2026-09-21"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04777396> ;
  onco:status "phase-3" ;
  onco:tag "dementia-atlas" ;
  onco:modality "small molecule" ;
  schema:alternateName "Ozempic / Rybelsus / Wegovy (other indications)" ;
  onco:cancers <https://onco.cc/diagnoses/alzheimers-disease/>, <https://onco.cc/diagnoses/mild-cognitive-impairment/> ;
  onco:companies <https://onco.cc/companies/da-novo/> ;
  onco:trials <https://onco.cc/trials/da-trial-evoke/> .